The estimated Net Worth of Edward J Sitar is at least $416 mil dollars as of 14 September 2021. Mr Sitar owns over 15,000 units of 9 Meters Biopharma stock worth over $13,604 and over the last 11 years he sold NMTR stock worth over $5,199. In addition, he makes $397,400 as Chief Financial Officer at 9 Meters Biopharma.
Sign up
Mr CPA NMTR stock SEC Form 4 insiders trading
Mr has made over 8 trades of the 9 Meters Biopharma stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of NMTR stock worth $18,300 on 14 September 2021.
The largest trade he's ever made was buying 61,538 units of 9 Meters Biopharma stock on 15 December 2020 worth over $40,000. On average, Mr trades about 8,081 units every 157 days since 2014. As of 14 September 2021 he still owns at least 194,338 units of 9 Meters Biopharma stock.
You can see the complete history of Mr Sitar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Edward J. Sitar CPA, CPA biography
Edward J. Sitar CPA, CPA is the Chief Financial Officer at 9 Meters Biopharma.
What is the salary of Mr CPA?
As the Chief Financial Officer of 9 Meters Biopharma, the total compensation of Mr CPA at 9 Meters Biopharma is $397,400. There are 2 executives at 9 Meters Biopharma getting paid more, with John Temperato having the highest compensation of $652,437.
How old is Mr CPA?
Mr CPA is 58, he's been the Chief Financial Officer of 9 Meters Biopharma since . There are 1 older and 2 younger executives at 9 Meters Biopharma. The oldest executive at 9 Meters Biopharma, Inc. is Dr. Patrick H. Griffin, 66, who is the Chief Medical Officer.
What's Mr CPA's mailing address?
Edward's mailing address filed with the SEC is C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT RD, STE 120, RALEIGH, NC, 27615.
Insiders trading at 9 Meters Biopharma
Over the last 4 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo y John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.
What does 9 Meters Biopharma do?
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.
What does 9 Meters Biopharma's logo look like?
Complete history of Mr Sitar stock trades at Cancer Genetics y 9 Meters Biopharma
9 Meters Biopharma executives and stock owners
9 Meters Biopharma executives and other stock owners filed with the SEC include:
-
John Temperato,
Pres, CEO & Director -
Dr. Patrick H. Griffin,
Chief Medical Officer -
Edward J. Sitar CPA, CPA,
Chief Financial Officer -
Sarah Liu M.B.A.,
Chief Commercial Officer -
Albert J. Medwar M.B.A., MBA,
Sr. VP of Investor Relations & Corp. Communications -
Bethany Sensenig C.M.A., M.B.A.,
Chief Financial Officer -
Dr. Nir Barak M.D.,
Sr. VP of Scientific Affairs -
Dr. Elena Verdu M.D., Ph.D.,
Clinical & Scientific Advisor and Consultant -
Dr. Ciaran P. Kelly M.D.,
Clinical & Scientific Advisor and Consultant -
Joseph A. Murray,
Clinical & Scientific Advisor and Consultant -
Dr. Peter H. R. Green M.D.,
Clinical & Scientific Advisor and Consultant -
Dr. Nir Barak,
Sr. VP of Scientific Affairs -
Jerry Gardner,
Head of Clinical Strategy -
Sireesh Appajosyula Pharm.D.,
Sr. VP of Corp. Devel. & Operations -
Samantha Ventimiglia,
Director -
Bethany Sensenig,
Chief Financial Officer -
John Temperato,
Chief Executive Officer -
Edward J Sitar,
Chief Financial Officer -
Lorin K Johnson,
Director -
Israel Gp Ltd.Orbi Med Isra...,
-
Nissim Darvish,
Director -
Sandeep Laumas,
Director -
Mark A Sirgo,
Director -
Saira Ramasastry,
Director -
Roy Proujansky,
Director -
Yehuda Michael Rice,
Director -
Jay P. Madan,
President -
Anthony E Iii Maida,
Director -
Michael T. Constantino,
Director